These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31433219)

  • 41. Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival.
    Gustafson TL; Kitchell BE; Biller B
    Vet Comp Oncol; 2017 Mar; 15(1):174-183. PubMed ID: 25864514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrasound characteristics of feline urinary bladder transitional cell carcinoma are similar to canine urinary bladder transitional cell carcinoma.
    Hamlin AN; Chadwick LE; Fox-Alvarez SA; Hostnik ET
    Vet Radiol Ultrasound; 2019 Sep; 60(5):552-559. PubMed ID: 31144408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
    Musser ML; Taikowski KL; Johannes CM; Bergman PJ
    BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
    Rossi F; Sabattini S; Vascellari M; Marconato L
    Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
    Upton ML; Tangner CH; Payton ME
    J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy.
    Bradbury ML; Mullin CM; Gillian SD; Weisse C; Bergman PJ; Morges MA; May LR; Vail DM; Clifford CA
    Can Vet J; 2021 Feb; 62(2):133-140. PubMed ID: 33542551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Piroxicam for bladder cancer.
    Barsanti JA
    J Vet Intern Med; 1995; 9(2):113-4. PubMed ID: 7760310
    [No Abstract]   [Full Text] [Related]  

  • 50. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors in dogs with urinary bladder carcinoma.
    Rocha TA; Mauldin GN; Patnaik AK; Bergman PJ
    J Vet Intern Med; 2000; 14(5):486-90. PubMed ID: 11012109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs: 24 cases (1985-2010).
    Higuchi T; Burcham GN; Childress MO; Rohleder JJ; Bonney PL; Ramos-Vara JA; Knapp DW
    J Am Vet Med Assoc; 2013 Feb; 242(4):499-506. PubMed ID: 23363282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical factors determining the efficacy of urinary bladder tumour treatments in dogs: surgery, chemotherapy or both?
    Molnár T; Vajdovich P
    Acta Vet Hung; 2012 Mar; 60(1):55-68. PubMed ID: 22366132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma.
    Vinall RL; Kent MS; deVere White RW
    Am J Vet Res; 2012 Oct; 73(10):1626-33. PubMed ID: 23013190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of transitional cell carcinoma of the urinary bladder in dogs: a review.
    Fulkerson CM; Knapp DW
    Vet J; 2015 Aug; 205(2):217-25. PubMed ID: 25747698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
    Prebble AR; Weishaar KM; Thamm DH; Leary D; LaRue SM; Martin T; Boss MK
    Vet Comp Oncol; 2022 Mar; 20(1):142-153. PubMed ID: 34310002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic role of ΔNp63 expression in canine transitional cell carcinoma of the urinary bladder.
    Nishimori T; Hanazono K; Matsuda K; Kawamura Y; Kadosawa T; Endo Y; Uchide T
    Open Vet J; 2021; 11(4):700-706. PubMed ID: 35070867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
    Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
    Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
    Pan X; Tsimbas K; Kurzman ID; Vail DM
    Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.